Fadraciclib

N/A

Report date: 2024/06/20 15:05:02
NME

Base Information

Drug NameFadraciclib
Drug Alias NameCYC-065
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 9 inhibitorsCyclin-dependent kinase 2 inhibitors
TargetsCyclin-dependent kinase 9Cyclin-dependent kinase 2
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesLymphoma +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSpainSouth Korea
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCyclacel Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesCyclacel Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursLymphomaLeukemia, Myeloid, Acute +[4] 
Inactive IndicationsMyelodysplastic SyndromesLeukemiaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A